Source: Clinical Endocrinology. Unidade: FM
Subjects: FENÓTIPOS, HIPERPLASIA SUPRARRENAL CONGÊNITA, HIDROXILASE (ATIVIDADE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, Rogério S. et al. Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation. Clinical Endocrinology, v. 62, p. 132-136, 2005Tradução . . Disponível em: https://doi.org/10.1111/j.1365-2265.2005.02184.x. Acesso em: 02 out. 2024.APA
Araujo, R. S., Billerbeck, A. E. C., Madureira, G., Mendonça, B. B., & Bachega, T. A. S. S. (2005). Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation. Clinical Endocrinology, 62, 132-136. doi:10.1111/j.1365-2265.2005.02184.xNLM
Araujo RS, Billerbeck AEC, Madureira G, Mendonça BB, Bachega TASS. Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation [Internet]. Clinical Endocrinology. 2005 ; 62 132-136.[citado 2024 out. 02 ] Available from: https://doi.org/10.1111/j.1365-2265.2005.02184.xVancouver
Araujo RS, Billerbeck AEC, Madureira G, Mendonça BB, Bachega TASS. Substitutions in the CYP21A2 promoter explain the simple-virilizing form of 21-hydroxylase deficiency in patients harbouring a P30L mutation [Internet]. Clinical Endocrinology. 2005 ; 62 132-136.[citado 2024 out. 02 ] Available from: https://doi.org/10.1111/j.1365-2265.2005.02184.x
